Beacon Pointe Advisors LLC Sells 1,237 Shares of Stryker Co. (NYSE:SYK)

Beacon Pointe Advisors LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 3.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,578 shares of the medical technology company’s stock after selling 1,237 shares during the quarter. Beacon Pointe Advisors LLC’s holdings in Stryker were worth $12,090,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of SYK. Morse Asset Management Inc lifted its holdings in shares of Stryker by 16.5% during the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after purchasing an additional 200 shares during the last quarter. World Investment Advisors LLC lifted its holdings in shares of Stryker by 126.1% during the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock valued at $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Arvest Bank Trust Division purchased a new stake in shares of Stryker during the 3rd quarter valued at $245,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of Stryker by 13.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock valued at $16,183,000 after purchasing an additional 5,361 shares during the last quarter. Finally, Tidal Investments LLC lifted its holdings in shares of Stryker by 13.9% during the 3rd quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock valued at $6,314,000 after purchasing an additional 2,139 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.4 %

Shares of SYK stock opened at $366.58 on Tuesday. The company’s 50-day moving average price is $367.37 and its 200-day moving average price is $373.51. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $139.92 billion, a price-to-earnings ratio of 47.24, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. As a group, equities analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker’s payout ratio is 43.30%.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. The Goldman Sachs Group set a $422.00 price objective on Stryker in a report on Tuesday, March 4th. Needham & Company LLC reiterated a “buy” rating and set a $442.00 price target on shares of Stryker in a research note on Friday, March 21st. JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a report on Monday, February 3rd. Finally, Barclays raised their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.